Danicopan, an Oral Complement Factor D Inhibitor, Exhibits High and Sustained Exposure in Ocular Tissues in Preclinical Studies

被引:14
作者
Boyer, David D. [1 ]
Ko, Ya-Ping [1 ]
Podos, Steven D. [1 ]
Cartwright, Mark E. [1 ]
Gao, Xiang [1 ]
Wiles, Jason A. [1 ]
Huang, Mingjun [1 ]
机构
[1] Alexion, AstraZeneca Rare Dis, 100 College St, New Haven, CT 06511 USA
关键词
ACH-4471; ACH-0144471; danicopan; ocular pharmacokinetics; age-related macular degeneration; alternative pathway inhibition; ALXN2040; complement; drug depot; geographic atrophy; melanin binding; retina; GEOGRAPHIC ATROPHY SECONDARY; RETINAL-PIGMENT EPITHELIUM; WHOLE-BODY AUTORADIOGRAPHY; MACULAR DEGENERATION; MELANIN BINDING; DRUGS; PATHWAY;
D O I
10.1167/tvst.11.10.37
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Complement alternative pathway (AP) dysregulation has been implicated in geographic atrophy, an advanced form of age-related macular degeneration. Danicopan is an investigational, first-in-class inhibitor of factor D, an essential AP activation enzyme. We assessed danicopan distribution to the posterior segment of the eye after oral dosing. Methods: Tissue distribution of drug-derived radioactivity was evaluated using wholebody autoradiography following oral administration of [14C]-danicopan to pigmented and albino rats. Pharmacokinetics and ocular tissue distribution were studied in pigmented and albino rabbits following single and multiple oral dosing of danicopan. The melanin binding property was characterized in vitro. Results: Radioactivity was distributed widely in rats and became nonquantifiable in most tissues 24 hours postdose except in the pigmented rat uvea (quantifiable 672 hours postdose). Danicopan binding to melanin was established in vitro. After single dosing, the maximum concentration (Cmax) and area under the curve (AUC) in neural retina and plasma were similar in both rabbit types. After multiple dosing, AUC in neural retina was 3.4-fold higher versus plasma in pigmented rabbits. Drug levels in choroid/Bruch's membrane (BrM)/retinal pigment epithelium (RPE) were similar to plasma in albino rabbits but higher in pigmented rabbits: Cmax and AUC were 2.9- and 23.8-fold higher versus plasma after single dosing and 5.8- and 62.7-fold higher after multiple dosing. In pigmented rabbits, ocular tissue exposures slowly declined over time but remained quantifiable 240 hours postdose. Conclusions: The results demonstrate that danicopan crosses the blood-retina barrier and binds melanin reversibly, leading to a higher and more sustained exposure in melanin-containing ocular tissues (choroid/BrM/RPE) and in the neural retina as compared to in plasma after repeated oral dosing in pigmented animals. Translational Relevance: These findings suggest that oral danicopan possesses potential for treating geographic atrophy because AP dysregulation in the posterior segment of the eye is reported to be involved in the disease pathogenesis.
引用
收藏
页数:11
相关论文
共 45 条
[1]   Lutein plus Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial [J].
Chew, Emily Y. ;
Clemons, Traci E. ;
SanGiovanni, John Paul ;
Danis, Ronald ;
Ferris, Frederick L., III ;
Elman, Michael ;
Antoszyk, Andrew ;
Ruby, Alan ;
Orth, David ;
Bressler, Susan ;
Fish, Gary ;
Hubbard, Baker ;
Klein, Michael ;
Chandra, Suresh ;
Blodi, Barbara ;
Domalpally, Amitha ;
Friberg, Thomas ;
Wong, Wai ;
Rosenfeld, Philip ;
Agron, Elvira ;
Toth, Cynthia ;
Bernstein, Paul ;
Sperduto, Robert .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 309 (19) :2005-2015
[2]   Ocular melanin binding of drugs: in vitro binding studies [J].
Bahrpeyma, Sina ;
Rimpela, Anna-Kaisa ;
Hagstrom, Marja ;
Urtti, Arto .
ACTA OPHTHALMOLOGICA, 2019, 97
[3]   THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET [J].
Boyer, David S. ;
Schmidt-Erfurth, Ursula ;
Campagne, Menno van Lookeren ;
Henry, Erin C. ;
Brittain, Christopher .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (05) :819-835
[4]  
ClinicalTrials.gov, CLG561 PROOF OF CONC
[5]  
ClinicalTrials.gov, STUD COMP EFF SAF IN
[6]  
ClinicalTrials.gov, PHAS 3 SAF EFF STUD
[7]  
ClinicalTrials.gov, INTR LFG316 PAT AG R
[8]   Pharmacokinetic aspects of retinal drug delivery [J].
del Amo, Eva M. ;
Rimpela, Anna-Kaisa ;
Heikkinen, Emma ;
Kari, Otto K. ;
Ramsay, Eva ;
Lajunen, Tatu ;
Schmitt, Mechthild ;
Pelkonen, Laura ;
Bhattacharya, Madhushree ;
Richardson, Dominique ;
Subrizi, Astrid ;
Turunen, Tiina ;
Reinisalo, Mika ;
Itkonen, Jaakko ;
Toropainen, Elisa ;
Casteleijn, Marco ;
Kidron, Heidi ;
Antopolsky, Maxim ;
Vellonen, Kati-Sisko ;
Ruponen, Marika ;
Urtti, Arto .
PROGRESS IN RETINAL AND EYE RESEARCH, 2017, 57 :134-185
[9]   Differential and Altered Spatial Distribution of Complement Expression in Age-Related Macular Degeneration [J].
Demirs, John T. ;
Yang, Junzheng ;
Crowley, Maura A. ;
Twarog, Michael ;
Delgado, Omar ;
Qiu, Yubin ;
Poor, Stephen ;
Rice, Dennis S. ;
Dryja, Thaddeus P. ;
Anderson, Karen ;
Liao, Sha-Mei .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (07)
[10]   Complement cascade inhibition in geographic atrophy: a review [J].
Desai, Dhaval ;
Dugel, Pravin U. .
EYE, 2022, 36 (02) :294-302